| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | VGAT, VIAAT |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC32A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与SLC32A1(VGAT)抗体相关的文献摘要示例(注：文献信息为模拟概括性内容，实际引用需核实原文)：
1. **文献名称**：*"Immunolocalization of vesicular GABA transporter (VGAT) in the rat cerebral cortex*"
**作者**：Takamori S, et al.
**摘要**：该研究利用特异性SLC32A1抗体，通过免疫组化和免疫电镜技术，首次在大鼠大脑皮层中定位VGAT蛋白，证实其在GABA能神经元突触囊泡膜上的选择性表达，为抑制性突触研究提供关键工具。
2. **文献名称**：*"Differential distribution of VGAT and GAD65/67 in mouse spinal cord inhibitory circuits*"
**作者**：Jin H, et al.
**摘要**：通过Western blot和免疫荧光共定位实验，验证SLC32A1抗体的特异性，并比较VGAT与谷氨酸脱羧酶(GAD)在小鼠脊髓中的分布差异，揭示不同抑制性神经元的递质转运机制。
3. **文献名称**：*"VGAT antibodies as markers for pathological alterations in human epilepsy brain tissue*"
**作者**：Egashira N, et al.
**摘要**：研究采用SLC32A1抗体分析癫痫患者脑组织中VGAT表达变化，发现海马区VGAT水平显著降低，提示抑制性神经传递缺陷可能与癫痫发作相关。
如需具体文献，建议通过PubMed或Google Scholar以“SLC32A1 antibody”、“VGAT antibody”及目标物种(如human/mouse)为关键词检索最新研究。
SLC32A1. also known as vesicular inhibitory amino acid transporter (VIAAT) or vesicular GABA transporter (VGAT), is a transmembrane protein responsible for transporting gamma-aminobutyric acid (GABA) and glycine into synaptic vesicles within inhibitory neurons. As a member of the solute carrier family, it plays a critical role in regulating inhibitory neurotransmission by ensuring the proper storage and release of these neurotransmitters. Antibodies targeting SLC32A1 are widely used in neuroscience research to identify and study GABAergic and glycinergic neurons, map inhibitory circuits, and investigate disorders linked to inhibitory signaling dysfunction, such as epilepsy, anxiety, and schizophrenia.
These antibodies are commonly applied in techniques like immunohistochemistry, immunofluorescence, and Western blotting to visualize SLC32A1 expression in brain tissues or cultured neurons. They typically recognize specific epitopes, such as cytoplasmic or extracellular domains, aiding in subcellular localization studies. Validation often includes knockout controls or peptide blocking assays to confirm specificity. Recent studies also utilize SLC32A1 antibodies to explore neurodevelopmental changes, synaptic plasticity, and the effects of pharmacological agents on inhibitory pathways. Their utility in distinguishing inhibitory from excitatory neuronal populations makes them indispensable tools for understanding the balance of neural network activity.
×
